Universal Beteiligungs und Servicegesellschaft mbH Sells 21,337 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Universal Beteiligungs und Servicegesellschaft mbH decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 157,253 shares of the biopharmaceutical company's stock after selling 21,337 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.14% of Regeneron Pharmaceuticals worth $99,735,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Choreo LLC raised its holdings in Regeneron Pharmaceuticals by 0.9% during the 1st quarter. Choreo LLC now owns 3,746 shares of the biopharmaceutical company's stock worth $2,376,000 after purchasing an additional 32 shares during the last quarter. Fagan Associates Inc. increased its stake in shares of Regeneron Pharmaceuticals by 1.6% in the 1st quarter. Fagan Associates Inc. now owns 13,126 shares of the biopharmaceutical company's stock valued at $8,325,000 after acquiring an additional 203 shares in the last quarter. Crestwood Advisors Group LLC boosted its stake in Regeneron Pharmaceuticals by 5.7% during the first quarter. Crestwood Advisors Group LLC now owns 467 shares of the biopharmaceutical company's stock worth $296,000 after acquiring an additional 25 shares in the last quarter. Los Angeles Capital Management LLC increased its position in Regeneron Pharmaceuticals by 1,376.2% in the 1st quarter. Los Angeles Capital Management LLC now owns 7,765 shares of the biopharmaceutical company's stock valued at $4,925,000 after buying an additional 7,239 shares in the last quarter. Finally, Lindbrook Capital LLC grew its stake in Regeneron Pharmaceuticals by 2.3% in the first quarter. Lindbrook Capital LLC now owns 1,177 shares of the biopharmaceutical company's stock valued at $746,000 after acquiring an additional 26 shares during the period. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on REGN. The Goldman Sachs Group reduced their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Robert W. Baird cut their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $700.00 to $580.00 in a report on Friday, May 30th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $837.61.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $7.97 during trading hours on Thursday, hitting $564.42. The stock had a trading volume of 534,552 shares, compared to its average volume of 1,122,220. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The firm has a market capitalization of $60.94 billion, a PE ratio of 14.37, a PEG ratio of 2.11 and a beta of 0.33. The stock has a fifty day moving average price of $543.59 and a 200 day moving average price of $611.77.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $9.55 earnings per share. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.62%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.